Clinical trials: Anti-coagulation Therapy
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT).
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
- Trial name
- NCT02860130
- Testing
- Prismocitrate 18, No Anticoagulation
- Where
- 12 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Vantive Health LLC
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
The goal of this study is to determine if a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) is as effective as the current standard of care.
- Conditions
- Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
- Trial name
- kcentra (NCT03064035)
- Testing
- 4-factor prothrombin complex concentrate (4FPCC)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- HealthPartners Institute
Acute Kidney Injury, Acute Renal Failure
A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation
Heparin is commonly used for anticoagulation of the extracorporeal circuit during continuous renal replacement therapy (CRRT) but the optimal mode of delivery has not yet been validated.
- Conditions
- Acute Kidney Injury, Acute Renal Failure, Heart Failure
- Trial name
- NCT01318811
- Testing
- Dilute unfractionated heparin, Standard concentration unfractionated heparin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University
Pulmonary Embolism, Deep Vein Thrombosis
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
In this research study, the investigators are trying to find a better way to set the dose of a common blood-thinning medication.
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation
- Trial name
- NCT00401414
- Testing
- Warfarin
- Where
- 2 sites in United States
- Volunteers
- 344 people
- Sponsor
- Brigham and Women's Hospital
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage
Anticoagulation With Enhanced Gastrointestinal Safety
This study is a pragmatic cluster randomized controlled trial to evaluate the effectiveness of a clinician-facing implementation strategy on the use of medication optimization (defined as either discontinuation of all…
- Conditions
- Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
- Trial name
- AEGIS (NCT05563714)
- Testing
- Clinician Notification with Nurse Facilitation (CNNF), Wait list control
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- University of Michigan
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
Coronary Artery Disease
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
The hypothesis: Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
- Trial name
- REDUCED (NCT01031095)
- Testing
- coronary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Bursa Postgraduate Hospital
Atrial Fibrillation
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
To describe the direct costs related to warfarin/apixaban treatment
- Trial name
- NCT04435769
- Where
- Czechia
- Volunteers
- 109 people
- Sponsor
- Pfizer
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Liver Cirrhosis, Portal Vein Thrombosis
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
- Trial name
- NCT04173429
- Testing
- Nadroparin calcium, warfarin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Qilu Hospital of Shandong University
Atrial Fibrillation, Medication Adherence
Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence
This is an interventional study designed to develop patient focused strategies that improve adherence to anticoagulant medication in patients with non-valvular atrial fibrillation (AF).
- Trial name
- NCT02690649
- Testing
- Health Messaging (Non-Procedural)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Tammy Toscos
COVID 19 Associated Coagulopathy
Covid-19 Associated Coagulopathy
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who…
- Trial name
- NCT04360824
- Testing
- Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- University of Iowa
Dementia, Cognition Disorders
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study.
- Conditions
- Dementia, Cognition Disorders, Cerebral Ischemic Events
- Trial name
- CAF (NCT03061006)
- Testing
- Dabigatran Etexilate, Warfarin
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Intermountain Health Care, Inc.